Suppr超能文献

氨鲁米特:一种化“副作用”为治疗优势的药物。

Aminoglutethimide: a "side-effect" turned to therapeutic advantage.

作者信息

Hughss S W, Burley D M

出版信息

Postgrad Med J. 1970 Jul;46(537):409-16. doi: 10.1136/pgmj.46.537.409.

Abstract

Aminoglutethimide was introduced as an anti-convulsant drug in the U.S.A. in 1960. The occurrence of a number of side-effects, including several endocrine effects such as goitrogenesis, sexual precocity and virilization, led to its withdrawal. Further investigation indicated that the drug inhibited adrenal biosynthesis, particularly of aldosterone, cortisol and androgens, probably by interfering with the conversion of cholesterol to delta-5-pregnenolone. Aminoglutethimide has also been shown to modify the extra-adrenal metabolism of cortisol. The possible clinical applications of these ‘side-effects’ are discussed.

摘要

1960年,氨鲁米特作为一种抗惊厥药物在美国被引入。由于出现了许多副作用,包括一些内分泌方面的影响,如甲状腺肿形成、性早熟和男性化,该药物被停用。进一步研究表明,该药物抑制肾上腺生物合成,特别是醛固酮、皮质醇和雄激素的合成,可能是通过干扰胆固醇向δ-5-孕烯醇酮的转化。氨鲁米特还被证明可以改变皮质醇的肾上腺外代谢。本文讨论了这些“副作用”可能的临床应用。

相似文献

引用本文的文献

4
Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma.
Br Med J. 1971 Nov 13;4(5784):391-4. doi: 10.1136/bmj.4.5784.391.
7
Could aminoglutethimide replace adrenalectomy?氨鲁米特能否替代肾上腺切除术?
Breast Cancer Res Treat. 1985;6(3):201-11. doi: 10.1007/BF01806770.
10
Drug-induced endocrine disorders.药物性内分泌紊乱。
Drugs. 1977 May;13(5):353-65. doi: 10.2165/00003495-197713050-00002.

本文引用的文献

1
The metabolism of gluethimide (Doriden).格鲁米特(多睡丹)的代谢
Experientia. 1962 Mar 15;18:105-11. doi: 10.1007/BF02153841.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验